Form 4: Xenon Pharmaceuticals CFO Sherry Aulin Granted Stock Options

Sherry Aulin, CFO of Xenon Pharmaceuticals, was granted stock options for 100,000 common shares on March 11, 2024, vesting over a three-year period.

Summary

• Sherry Aulin, the Chief Financial Officer of Xenon Pharmaceuticals Inc., was granted stock options on March 11, 2024.
• The options are for 100,000 common shares of Xenon Pharmaceuticals.
• The exercise price of the options is $44.37 per share.
• The options vest 25% on January 1, 2025, and the remaining 75% vest over the following three years in equal monthly installments.
• The options expire on March 10, 2034.
• A power of attorney was executed on March 7, 2024, granting Andrea DiFabio, Ilona Lo, and Nathaniel Adams the authority to file SEC documents on Aulin's behalf.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. The sentiment is neutral to slightly positive.

Positives

• The granting of stock options to the CFO aligns her interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CFO.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance, but the stock option grant suggests an expectation of continued contributions from the CFO.

Industry Context

Stock option grants are a common practice in the pharmaceutical industry to incentivize key executives and align their interests with those of the shareholders. This is a standard compensation practice.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the pharmaceutical industry.
• Companies like Amgen, Biogen, and Gilead Sciences also utilize stock options as part of their executive compensation plans.
• The vesting schedule and exercise price are generally determined based on the executive's role, performance, and industry benchmarks.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the CFO to improve company performance.
• Employees may see the grant as a sign of confidence in the company's future.

Key Dates